Paul Truex is the Chairman and CEO of Thryv Therapeutics, bringing nearly three decades of experience in life sciences. Over his career, he has played a pivotal role in more than $5 billion in life sciences financings and strategic transactions.  

Before joining Thryv, Paul founded Anthera Pharmaceuticals, a publicly traded biotech company with significant clinical programs in cardiovascular disease, lupus, inflammation, and cystic fibrosis. He also served as Founder, President, and CEO of Peninsula Pharmaceuticals, an antibiotic development company acquired by Johnson & Johnson and Forest Laboratories for over $700 million. 

Paul began his career in life sciences at Eli Lilly and Company, where he gained experience in business development, including the Lilly ICOS joint venture for the development of Cialis® and several successful out-licensing initiatives. 

Paul currently serves on the boards of Feldan Therapeutics, Find Therapeutics, and Thryv. He is a former board member of Milestone (Nasdaq: MIST), Anthera (Nasdaq: ANTH), Trius (acquired), CymaBay (acquired), Eiger (EIGR), Protagonist (PTGX), and Peninsula Pharmaceuticals (acquired). 

He obtained his Master of Business Administration from Indiana University and a Bachelor of Arts in Economics from the University of Waterloo. Paul also serves as an Acting Board Member for the Indiana University Johnson Center for Entrepreneurship and Innovation. 

Dr. Debra Odink is the President and Chief Development Officer of Thryv Therapeutics. With over 30 years of experience, she has played a pivotal role in the pharmaceutical development of both large and small molecules across multiple therapeutic areas. 

Dr. Odink began her career at Roche, where she worked in manufacturing process development and the characterization of several early-stage programs. She then transitioned into the start-up, venture-backed biotech sector, starting with Peninsula Pharmaceuticals, where she advanced a sterile-filled antibiotic from pre-clinical development to NDA, ultimately leading to its acquisition by Johnson & Johnson. 

As Chief of Technical Operations at Anthera Pharmaceuticals, Dr. Odink advanced multiple products ranging from cardiovascular indications to autoimmune disorders into Phase 3. At Eiger Biopharmaceuticals, as Senior Vice President of Technical Operations, she led the advancement of small molecule, peptide and biologic therapeutics into four rare disease programs, one of which was recently approved. Most recently, at SiteOne Therapeutics, she served as Chief Development Officer, where she was instrumental in advancing a novel non-opioid pain therapeutic into clinical trials. 

Dr. Odink holds a Ph.D. in Chemistry from the University of California, Davis, and a B.S. in Chemistry from California State University, Stanislaus. 

Dr. Amy Sehnert is the Chief Medical Officer of Thryv Therapeutics. A pediatric cardiologist and physician-scientist, Dr. Sehnert began her academic career at UCSF and Stanford University, before gaining over 20 years of experience as an executive clinical leader in developing and launching precision diagnostics and therapeutics for patients. 

Prior to joining Thryv, Dr. Sehnert was Vice President and Global Program Lead at Bristol Myers Squibb (BMS), where she led cardiovascular transition assets targeting cardiomyopathies and heart failure. She joined BMS through the acquisition of MyoKardia, Inc., where she served as Vice President of Clinical Science. In this role, she led the pivotal Phase 3 EXPLORER-HCM trial of mavacamten, contributing to the global regulatory filings that resulted in the approval of Camzyos® (a first-in-class treatment for symptomatic obstructive hypertrophic cardiomyopathy) in 45 countries, starting with the US FDA in April 2022. She also spearheaded Phase 2, 3, and long-term extension studies of mavacamten, helping to integrate it into practice guidelines in the US and EU. 

Dr. Sehnert has also made significant contributions in genomic diagnostics, working with companies such as CardioDx, Verinata Health, Illumina, and GRAIL. Her work in noninvasive prenatal testing (NIPT) and oncology screening through cell-free DNA sequencing technologies has had a lasting impact on these fields. Throughout her career, she has co-authored over 60 publications in top-tier journals. 

In 2022, Dr. Sehnert was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. 

Dr. Sehnert holds a bachelor's degree in mechanical engineering and a Doctor of Medicine from the University of Minnesota, where she currently serves on the Medical School Alumni Board. She completed her residency in Pediatrics at the University of Colorado/The Children’s Hospital and fellowship in Pediatric Cardiology at UCSF, where she was a fellow in the Pediatric Scientist Training Program. She later served as an assistant professor and principal investigator of NIH-K08, American Heart Association young investigator, and institution-based grants. 

Dr. Matt Killeen is the Chief Business Officer of Thryv Therapeutics.

Dr. Killeen brings nearly two decades of biopharmaceutical industry experience to Thryv, with deep expertise across portfolio strategy, business development, commercial strategy, and R&D leadership in cardiometabolic, rare/genetic, and CNS diseases. His career reflects a consistent focus on advancing first-in-class therapies and guiding strategic initiatives across multiple organizations.

Dr. Killeen previously founded the precision cardiology therapeutic area at BioMarin, where he served as Head of Cardiovascular R&D and built a portfolio of genetic therapies for inherited heart diseases. He then became the first Chief Scientific Officer of Renovacor (acquired by Rocket Pharmaceuticals), leading the development of gene therapies for genetic cardiomyopathies. Most recently, Dr. Killeen served as President of TikkunLev Therapeutics, where he launched the company and advanced a novel gene therapy for heart failure.

Earlier in his career, Dr. Killeen contributed to three CNS product launches at Biogen, led portfolio strategy efforts at BioMarin, and worked as a strategy consultant advising global biopharma companies in the US and Europe.

Dr. Killeen earned his Ph.D. in cardiac electrophysiology from the University of Cambridge and completed postdoctoral training as a research fellow at Harvard Medical School and Massachusetts General Hospital. He has authored more than 25 publications and is an elected Fellow of the Heart Rhythm Society, the American College of Cardiology, and the Royal Society of Biology.

Dr. Saumya Das, MD, PhD, is a Professor of Medicine at Harvard Medical School, a faculty member of the Cardiac Arrhythmia Service, and the co-Director of the Inherited Arrhythmia Program at Massachusetts General Hospital (MGH). 

Dr. Das completed his residency in internal medicine at MGH, followed by fellowship training in cardiovascular disease and clinical cardiac electrophysiology at MGH. He then undertook a research post-doctoral fellowship with Dr. Rosenzweig, studying signaling pathways in cardiac electrical remodeling, before starting his own laboratory at Beth Israel Deaconess Medical Center in 2011. He was recruited to MGH in 2016. His research focuses on signaling pathways in electrical and structural remodeling in models of heart failure and cardiometabolic disease, with particular emphasis on extracellular vesicles and their cargo RNAs as biomarkers and mediators of intercellular signaling. 

Dr. Das has served as the lead Principal Investigator (PI) of several National Center for Advanced Translational (NCAT) grants aimed at discovering and validating RNA biomarkers of heart remodeling in heart failure. As part of the NIH Extracellular RNA Communication Consortium, he co-chaired the steering committee. He was inducted into the American Society of Clinical Investigation in 2020 and received the NIH EIA award (R35). 

Research conducted in Dr. Das’s laboratory has led to several patents. He is a co-founder of Thryv Therapeutics and Switch Therapeutics, based on discoveries made in his lab. 

Dr. Das graduated summa cum laude in Biology from Harvard College, earned his MD from Harvard Medical School, and his PhD from the Harvard Graduate School of Arts and Sciences. 

Ms. Aidan McNeil is Senior Vice President, Administration and Associate General Counsel at Thryv Therapeutics. She is responsible for all legal and administrative matters for the company.

Prior to joining Thryv, she practised law for 8 years in the corporate law group at Osler, Hoskin & Harcourt LLP, primarily in corporate finance and mergers and acquisitions, with a particular focus on venture backed emerging and high growth companies. She also spent 8 years as in-house counsel in the Legal Department at McKesson Canada, where she advised on multiple acquisitions and divestitures and was responsible for the legal affairs for numerous business units, including the specialty pharmaceutical and patient support programs businesses. While at McKesson Canada, she was also responsible for all legal matters associated with the establishment of a national network of infusion clinics for various biologics and other infusion medications.

Ms. McNeil holds a Bachelor of Arts in International Development Studies from the University of Winnipeg and a Juris Doctor (JD) and a Bachelor of Civil Law (BCL) from McGill University.

Dr. Ravi Shah, MD, is a Professor of Medicine at Vanderbilt University Medical Center, where he serves as the Director of Clinical and Translational Research in Cardiovascular Medicine. He specializes in the treatment of patients with advanced heart failure. 

Dr. Shah completed his residency in internal medicine, followed by fellowships in cardiovascular medicine and advanced heart failure and transplantation at Massachusetts General Hospital. He then pursued a post-doctoral fellowship with Dr. Saumya Das and Dr. Raymond Kwong, studying the impact of non-coding RNAs on cardiac remodeling. He currently leads a laboratory at Vanderbilt University Medical Center focused on the functional biology and molecular epidemiology of cardiometabolic diseases and heart failure. His research is funded by the National Institutes of Health (NIH) and the American Heart Association (AHA), and has been published in leading journals including Circulation, Nature Medicine, Circulation Research, and the Journal of the American College of Cardiology. 

Dr. Shah graduated summa cum laude in Chemistry from Harvard College and earned his MD from Harvard Medical School. 

Dr. Marc Vidal serves as Vice President of Chemistry at Thryv Therapeutics, where he leads the company’s chemistry initiatives, including drug design and CMC operations. 

Prior to joining Thryv, Dr. Vidal worked at Gladius Pharmaceuticals from 2016 to 2019, initially as a Research Scientist, where he designed and executed multi-step syntheses to develop a library of cephalosporin-based compounds targeting multi-drug-resistant bacterial infections. He later advanced to Head of Chemistry, overseeing CMC operations and compound development. 

Dr. Vidal earned his chemical engineering degree from École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN) in France. He then obtained his PhD in Organic Chemistry from the Université de Montréal, where he developed and studied a novel class of anion transporters. Following his PhD, he pursued postdoctoral research at the Université de Montréal, focusing on molecularly imprinted polymers for the capture of small compounds. 

Dr. Alexandre Brkovic serves as Vice President of Clinical Research at Thryv Therapeutics, bringing over a decade of experience in the pharmaceutical industry across project management, clinical operations, and pharmacokinetics. 

Prior to joining Thryv, Dr. Brkovic was Senior Manager of Clinical Trials at Bausch Health (and later Bausch + Lomb following its spin-off), where he managed medical device and pharmaceutical studies spanning Phase 1 to 4 across multiple therapeutic areas, including dermatology, ophthalmology, and infectious diseases. Before that, he was Manager of Clinical Trials at Jubilant DraxImage, overseeing a therapeutic radiopharmaceutical investigational product in Phase 2, Phase 3, and an expanded access program for an ultra-rare pediatric oncology disease. 

Dr. Brkovic began his pharmaceutical career at Pharmascience, where he held roles of increasing responsibility. Before his departure, he served as Director of Biopharmaceutics, leading clinical trial execution and managing a team of scientists and clinical research associates. 

Dr. Brkovic holds a bachelor's degree in Biochemistry from the Université du Québec à Montréal (UQAM), a master's degree in Experimental Health Sciences from INRS-Institute Armand-Frappier, and a PhD in Pharmacology from the Université de Montréal (UdeM). 

Curtis McGrath, CPA, serves as Vice President of Finance at Thryv Therapeutics, where he leads the company’s financial strategy, business development, and investor relations. With a strong foundation in corporate finance and accounting, he plays a key role in supporting the company’s financial objectives. 

Curtis holds a Bachelor of Business Administration in Accounting, Audit, and Information Technology from Conestoga College and is a Chartered Professional Accountant (CPA). He began his career in public accounting as a staff accountant, gaining valuable experience working with diverse clients across various industries. 

Dr. Eric Campeau is the Vice President of Translational Research at Thryv Therapeutics, where he leads efforts to advance the development of SGK1 inhibitors from the laboratory to clinical trials as innovative therapies for cardiometabolic diseases and cancer. With more than 30 years of biomedical research experience, Dr. Campeau most previously served as Vice President of Translational Biology at Zenith Epigenetics Ltd. His research has contributed to several publications in the fields of epigenetics, cancer, DNA repair, and metabolism. 

Dr. Campeau played a pivotal role in the preclinical and clinical development of ZEN-3694 since the founding of Zenith in 2013. Notably, his leadership of the Translational Medicine team was instrumental in designing a patient pre-selection approach for a randomized study in metastatic castration-resistant prostate cancer. Before joining Zenith, Dr. Campeau was a Scientist at Resverlogix Corp. (2011) and held academic positions, including as an Instructor at the University of Massachusetts Medical School and a Scientist at the Lawrence Berkeley National Laboratory. 

Dr. Campeau holds a bachelor's degree in biology and a Ph.D. in Human Genetics from McGill University. He is also a certified Project Management Professional (PMP). 

Delphine Labit is the Director of Research, Translational Research at Thryv Therapeutics, where she leads studies focused on the impact of SGK1 inhibitors in oncology and other therapeutic areas. Delphine joined Thryv in early 2022 and brings over 20 years of industry experience in scientific research. Her expertise includes cellular and pharmacodynamic small molecule research and bioanalytical analysis in a GLP environment. Delphine specializes in drug development for oncology, immunology, and other applications. 

Before joining Thryv Therapeutics, Delphine served as Principal Investigator for immunogenicity assays at Altasciences, where she established the Cellular Biology Unit within the Ligand Binding Assay department. Prior to that, she spent 16 years at Aegera Therapeutics, contributing to the development of kinase inhibitors for B cell malignancies and small molecule inhibitors targeting Inhibitor of Apoptosis Proteins (IAPs). 

Delphine holds an MSc in Applied Molecular Cytology from Montpellier II University and a Master’s in Genetics from Paris-Diderot University in France. Her extensive experience and dedication to advancing drug development make her a valuable asset to the Thryv team. 

Dr. Maroua Khalifa serves as the Associate Director of Pharmaceutical Development at Thryv Therapeutics, where she leads CMC operations across multiple programs. Prior to joining Thryv, Dr. Khalifa was a consultant at Gladius Pharmaceuticals, where she successfully scaled up the synthesis of the lead candidate to gram scale for preclinical studies targeting multi-drug-resistant bacterial infections. 

Earlier in her career, Dr. Khalifa worked as a project manager at Novalix-Tunisia, where she played a pivotal role in establishing the first R&D laboratory in North Africa, laying the foundation for future research and development initiatives in the region. 

Dr. Khalifa holds a bachelor’s and master's degree in Organic Chemistry from the Université de Monastir in Tunisia. She earned her Ph.D. in Organic Chemistry from the Université de Montréal, where she developed an innovative intramolecular C-H amination reaction using a Rhodium complex catalyst. This methodology contributed to the formal synthesis of (-)-Cytoxazone, a selective immunomodulator that inhibits the signaling pathway of Th2 cells. 

Justine Keller serves as Financial Controller at Thryv Therapeutics, where she oversees all financial activities, ensuring compliance with regulatory requirements and providing strategic financial reporting to the senior management team. 

Before joining Thryv Therapeutics, Justine worked as a financial consultant for various biotech companies in Montreal, offering strategic financial guidance to help them scale for growth. Prior to her consulting career, she served as Finance Manager for over five years, specializing in process development and software implementations for companies like Mitsubishi Aircraft and Valsoft Corporation. 

Justine holds a bachelor's degree in finance and accounting from McGill University and brings over 10 years of experience in finance management and consulting across several industries, with expertise in aerospace, software, and biotech. 

Dr. Sabindra Pradhananga serves as Principal Research Scientist at Thryv Therapeutics. Although a registered Pharmacist, his passion lies in identifying and developing novel drug candidates. 

Prior to joining Thryv, Dr. Pradhananga worked as a Quality Control Officer at Omnica Laboratories, where he contributed to ensuring that the manufactured pharmaceutical products complied with pharmacopeial regulations. 

Dr. Pradhananga received his degree in Pharmacy from The T.N. Dr. M.G.R. Medical University in India. He holds a master's degree in Pathophysiology from Gachon University in South Korea, where he investigated the potency of caffeic acid as a potential anti-itch drug. He earned his Ph.D. in Neuroscience from Queen’s University in Canada, where he studied the mechanisms of interaction between gut microbiota and the vagus nerve and the role of this interaction in colitis. 

Dr. Julie Vatté is a Research Scientist at Thryv Therapeutics, where she plays a key role in the design and synthesis of a novel library of SGK1 inhibitors. Previously, she worked as an Organic Chemist at C/D/N Isotopes (LGC Standard), a global leader in the production of deuterium-labeled compounds. 

Dr. Vatté holds a degree in Chemical Engineering from CPE Lyon in France. She completed her Ph.D. in Organic Chemistry at Université de Montréal in Canada, where her research focused on developing dual inhibitors targeting the energy metabolism of cancer cells. Additionally, she designed bifunctional molecules, such as PROTACs and AUTACs, aimed at facilitating protein degradation and autophagy. 

Shannon Hewgill serves as a Research Associate at Thryv Therapeutics, where she studies the role of SGK1 in the immune system and fibrosis. She specializes in cell-based assays using small molecule inhibitors, immune profiling using flow cytometry, and a range of molecular biology techniques. 

Shannon holds an MSc in Microbiology & Immunology from McGill University, where she researched lipid metabolism and its role in allergic lung inflammation. After completing her MSc, Shannon gained valuable experience working in a CRO setting before joining Thryv in 2022. Alongside her work at Thryv, Shannon recently earned a Certificate in Biomedical Visualization and Communication from the University of British Columbia. 

Brittany Hagen serves as Manager of Corporate Communications & Office at Thryv Therapeutics, where she leads Thryv’s communications, manages collaborations with advocacy organizations, oversees all social media and marketing initiatives, and handles administrative and office functions. 

Before joining Thryv Therapeutics, Brittany gained experience in corporate coordination, product management, logistics, and customer service. 

Brittany holds a Bachelor of Arts (Honours) in Environmental and Global Development Studies from Queen’s University, where she graduated with distinction. She also earned a Graduate Certificate in Marketing from McGill University.